Article
Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) - 1 Jul 2011
Liu Li, Yuan Peng, Wu Chen, Zhang Xiaomin, Wang Feng, Guo Huan, Zhong Rong, Xu Yihua, Wu Jing, Yu Dianke, Wu Tangchun, Zhang Xuemei, Nie Shaofa, Miao Xiaoping, Lin Dongxin
Abstract excerpt
Polymorphisms in DNA repair genes were thought to represent important determinants of platinum drug efficacy. This study tested whether XPD Lys751Gln and XRCC1 T-77C polymorphisms were associated with survival in platinum-treated patients with advanced non-small-cell lung cancer (NSCLC). In this study, 199 advanced NSCLC patients with platinum-based chemotherapy were recruited. During the median 26.5 months of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
